ATE221048T1 - Fluorierte prostaglandinderivate und medikamente - Google Patents

Fluorierte prostaglandinderivate und medikamente

Info

Publication number
ATE221048T1
ATE221048T1 AT97940373T AT97940373T ATE221048T1 AT E221048 T1 ATE221048 T1 AT E221048T1 AT 97940373 T AT97940373 T AT 97940373T AT 97940373 T AT97940373 T AT 97940373T AT E221048 T1 ATE221048 T1 AT E221048T1
Authority
AT
Austria
Prior art keywords
group
medicine
hydrogen atoms
double bond
eye disease
Prior art date
Application number
AT97940373T
Other languages
English (en)
Inventor
Eiichi Shirasawa
Takayama-Cho
Masaaki Kageyama
Nobuaki Mori
Kanagawa-Ku Cho
Kazuhisa Sakata
Takashi Nakano
Yasushi Matsumura
Yoshitomi Morizawa
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27276117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE221048(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP8346286A external-priority patent/JPH10182598A/ja
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ATE221048T1 publication Critical patent/ATE221048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT97940373T 1996-09-17 1997-09-12 Fluorierte prostaglandinderivate und medikamente ATE221048T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP24515596 1996-09-17
JP8346286A JPH10182598A (ja) 1996-12-25 1996-12-25 含フッ素プロスタグランジン誘導体の製造方法
JP410997 1997-01-13
PCT/JP1997/003236 WO1998012175A1 (en) 1996-09-17 1997-09-12 Fluorinated prostaglandin derivatives and medicines

Publications (1)

Publication Number Publication Date
ATE221048T1 true ATE221048T1 (de) 2002-08-15

Family

ID=27276117

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940373T ATE221048T1 (de) 1996-09-17 1997-09-12 Fluorierte prostaglandinderivate und medikamente

Country Status (4)

Country Link
EP (1) EP0930296B2 (de)
AT (1) ATE221048T1 (de)
DE (1) DE69714274T3 (de)
WO (1) WO1998012175A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
HUP0004436A3 (en) * 1997-09-09 2001-09-28 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
SK3382000A3 (en) * 1997-09-09 2000-10-09 Procter & Gamble A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders
BR9811774A (pt) * 1997-09-09 2000-08-29 Procter & Gamble Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
RU2414904C2 (ru) 2005-03-31 2011-03-27 Асахи Гласс Компани, Лимитед ЗАЩИТНОЕ СРЕДСТВО ДЛЯ НЕЙРОНА СЕТЧАТКИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО КОМПОНЕНТА ПРОИЗВОДНОЕ ПРОСТАГЛАНДИНА F2α
RU2392938C2 (ru) 2005-04-13 2010-06-27 Убе Индастриз, Лтд Защитное средство для нейронных клеток сетчатки, содержащее в качестве активного ингредиента производные индазола
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3828172A1 (de) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2018183911A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348437A3 (de) * 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandinderivative zur Behandlung von Glaukoma oder okuläre Hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) † 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
US6649653B1 (en) * 1996-11-12 2003-11-18 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
SK3382000A3 (en) * 1997-09-09 2000-10-09 Procter & Gamble A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders
US9259564B2 (en) † 2009-01-22 2016-02-16 Avent, Inc. Enteral feeding assembly with lock assembly

Also Published As

Publication number Publication date
DE69714274D1 (de) 2002-08-29
EP0930296A4 (de) 1999-11-17
EP0930296B1 (de) 2002-07-24
EP0930296A1 (de) 1999-07-21
WO1998012175A1 (en) 1998-03-26
EP0930296B2 (de) 2005-11-02
DE69714274T2 (de) 2003-03-27
DE69714274T3 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
DE69714274D1 (de) Fluorierte prostaglandinderivate und medikamente
NO2009006I2 (no) isopropyl(5Z)-7{(1R, 2R, 3R, 5S)-2-[(IE)-3,3-difluor-4-fenoksybut-l-enyl]-3,5-dihydroksycyklopentyl}hept-5-enoat eller 16-fenoksy-15-deoksy-15,15-difluor-17,18,19,20-tetranorprostaglandin F2a isopropyl ester
DK0644199T3 (da) Cykliske antimikrobielle peptider og fremstilling deraf
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
EA200100916A1 (ru) Лекарственное средство, содержащее производное сульфопиранозилацилглицерина
ATE223411T1 (de) 1-methylcarbapenem-derivate
AU641686B2 (en) Benzanilides
DE69425970D1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
KR960703843A (ko) 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties